Japanese Encephalitis Vaccine, Live

ApprovedVaccine

LLiaoning Chengda Biotechnology CO., LTD

Japanese Encephalitis Vaccine, Live is one of 20 biologic programs targeting Japanese encephalitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Japanese EncephalitisActive, not recruiting

Japanese EncephalitisApproved

Active, not recruiting

Competition

Competitive Landscape

49 competitors in Japanese Encephalitis

#DrugCompanyPhaseTrials

Hepatitis a Vaccine

Sanofi

Phase 3

1 2

Prevnar

GSK

Phase 3

1 3

Havrix

GSK

Phase 3

1 4

Measles Vaccine

GSK

Phase 3

1 5

Rituxan

Roche

Phase 2

—6

Measles-Mumps-Rubella Vaccine

LLiaoning Chengda Biotechnology CO., LTD

Approved

2 7

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

1 8

Varicella Vaccine

Sanofi

Phase 3

1 9

Japanese Encephalitis Vaccine, Live

LLiaoning Chengda Biotechnology CO., LTD

Approved

2 10

Immunoglobulin

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Post-ApprovalActive, not recruiting

Japanese Encephalitis

NCT06825312

Clinical

Trials by Indication[1]

Japanese encephalitis2 trials

Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis

Active, not recruiting·LLiaoning Chengda Biotechnology CO., LTD·Phase 4·NCT06825312·600 enrolled

Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province

Unknown status·ZZhejiang Provincial Center for Disease Control and Prevention·Phase 4·NCT04817917·712 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Japanese Encephalitis Vaccine, Live. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Japanese Encephalitis Vaccine, Live compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Japanese Encephalitis Vaccine, Live. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liaoning Chengda Biotechnology CO., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Approved[1]
Company: LLiaoning Chengda Biotechnology CO., LTD

Japanese Encephalitis Vaccine, Live

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2031

Trials by Indication[1]

Japanese encephalitis2 trials

References

Drug Info

Quick Facts

Related News